Interleukin 2 là gì? Các công bố khoa học về Interleukin 2

Interleukin 2 (IL-2) is a protein that is produced by certain white blood cells and plays a key role in the immune system. It is a type of cytokine, which are s...

Interleukin 2 (IL-2) is a protein that is produced by certain white blood cells and plays a key role in the immune system. It is a type of cytokine, which are signaling molecules that help to regulate the immune response. IL-2 stimulates the growth and activity of various immune cells, including T cells and natural killer (NK) cells, and is important for the body's ability to respond to infections and cancer. IL-2 has been used in the treatment of certain types of cancer, such as melanoma and renal cell carcinoma, as well as in the treatment of some autoimmune diseases. However, it can also have serious side effects and is not suitable for all patients.
Interleukin 2 has a range of effects on the immune system. It is mainly produced by activated T cells and helps to regulate the activity of other immune cells. IL-2 promotes the proliferation and differentiation of T cells, helping to amplify the immune response to infections and cancer. It also plays a role in the development and maintenance of regulatory T cells, which helps to prevent excessive immune responses that could lead to autoimmune diseases.

In addition to its role in the immune system, IL-2 has been used as a therapy for certain medical conditions. High-dose IL-2 has been used in the treatment of metastatic melanoma and renal cell carcinoma, as it has been shown to induce durable remissions in a small percentage of patients. However, its use is limited due to significant toxicities and side effects, including flu-like symptoms, low blood pressure, and organ toxicity.

Because of the complexities and potential risks associated with IL-2 therapy, its use is carefully considered and typically reserved for patients with advanced cancer who have not responded to other treatments. Research continues into the potential of IL-2 and its derivatives for treating various diseases and conditions, and efforts are ongoing to develop safer and more effective forms of IL-2 therapy.
Ngoài ra, nghiên cứu cũng đã chỉ ra rằng IL-2 có thể được sử dụng để điều trị một số bệnh autoimmune, trong đó bao gồm viêm khớp dạng thấp và bệnh lupus. Việc sử dụng IL-2 trong điều trị các bệnh tự miễn dịch đang được nghiên cứu một cách tích cực. IL-2 cũng đã được nghiên cứu trong việc cấy ghép tế bào gốc và trong việc kích thích hoạt động miễn dịch sau cấy ghép tế bào gốc.

Ngoài ra, các dạng tương tự của IL-2 đã được phát triển để tăng cường hiệu quả và giảm độc tính, trong đó có các dạng tái cấu trúc của IL-2 và các dạng kết hợp của IL-2 với kháng thể để tăng cường sự tiếp nhận tế bào mục tiêu. Các nghiên cứu đang tiếp tục để nghiên cứu các ứng dụng tiềm năng của IL-2 và các phương pháp điều chỉnh hiệu quả của nó trong điều trị các bệnh lý miễn dịch và ung thư.

Danh sách công bố khoa học về chủ đề "interleukin 2":

C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus
JAMA - Journal of the American Medical Association - Tập 286 Số 3 - Trang 327 - 2001
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
Nature Immunology - Tập 6 Số 11 - Trang 1133-1141 - 2005
Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes.
Journal of Experimental Medicine - Tập 174 Số 5 - Trang 1209-1220 - 1991
In the present study we demonstrate that human monocytes activated by lipopolysaccharides (LPS) were able to produce high levels of interleukin 10 (IL-10), previously designated cytokine synthesis inhibitory factor (CSIF), in a dose dependent fashion. IL-10 was detectable 7 h after activation of the monocytes and maximal levels of IL-10 production were observed after 24-48 h. These kinetics indicated that the production of IL-10 by human monocytes was relatively late as compared to the production of IL-1 alpha, IL-1 beta, IL-6, IL-8, tumor necrosis factor alpha (TNF alpha), and granulocyte colony-stimulating factor (G-CSF), which were all secreted at high levels 4-8 h after activation. The production of IL-10 by LPS activated monocytes was, similar to that of IL-1 alpha, IL-1 beta, IL-6, IL-8, TNF alpha, granulocyte-macrophage colony-stimulating factor (GM-CSF), and G-CSF, inhibited by IL-4. Furthermore we demonstrate here that IL-10, added to monocytes, activated by interferon gamma (IFN-gamma), LPS, or combinations of LPS and IFN-gamma at the onset of the cultures, strongly inhibited the production of IL-1 alpha, IL-1 beta, IL-6, IL-8, TNF alpha, GM-CSF, and G-CSF at the transcriptional level. Viral-IL-10, which has similar biological activities on human cells, also inhibited the production of TNF alpha and GM-CSF by monocytes following LPS activation. Activation of monocytes by LPS in the presence of neutralizing anti-IL-10 monoclonal antibodies resulted in the production of higher amounts of cytokines relative to LPS treatment alone, indicating that endogenously produced IL-10 inhibited the production of IL-1 alpha, IL-1 beta, IL-6, IL-8, TNF alpha, GM-CSF, and G-CSF. In addition, IL-10 had autoregulatory effects since it strongly inhibited IL-10 mRNA synthesis in LPS activated monocytes. Furthermore, endogenously produced IL-10 was found to be responsible for the reduction in class II major histocompatibility complex (MHC) expression following activation of monocytes with LPS. Taken together our results indicate that IL-10 has important regulatory effects on immunological and inflammatory responses because of its capacity to downregulate class II MHC expression and to inhibit the production of proinflammatory cytokines by monocytes.
Interleukin-12 and the regulation of innate resistance and adaptive immunity
Nature Reviews Immunology - Tập 3 Số 2 - Trang 133-146 - 2003
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
Biochemical Journal - Tập 374 Số 1 - Trang 1-20 - 2003
The IL (interleukin)-6-type cytokines IL-6, IL-11, LIF (leukaemia inhibitory factor), OSM (oncostatin M), ciliary neurotrophic factor, cardiotrophin-1 and cardiotrophin-like cytokine are an important family of mediators involved in the regulation of the acute-phase response to injury and infection. Besides their functions in inflammation and the immune response, these cytokines play also a crucial role in haematopoiesis, liver and neuronal regeneration, embryonal development and fertility. Dysregulation of IL-6-type cytokine signalling contributes to the onset and maintenance of several diseases, such as rheumatoid arthritis, inflammatory bowel disease, osteoporosis, multiple sclerosis and various types of cancer (e.g. multiple myeloma and prostate cancer). IL-6-type cytokines exert their action via the signal transducers gp (glycoprotein) 130, LIF receptor and OSM receptor leading to the activation of the JAK/STAT (Janus kinase/signal transducer and activator of transcription) and MAPK (mitogen-activated protein kinase) cascades. This review focuses on recent progress in the understanding of the molecular mechanisms of IL-6-type cytokine signal transduction. Emphasis is put on the termination and modulation of the JAK/STAT signalling pathway mediated by tyrosine phosphatases, the SOCS (suppressor of cytokine signalling) feedback inhibitors and PIAS (protein inhibitor of activated STAT) proteins. Also the cross-talk between the JAK/STAT pathway with other signalling cascades is discussed.
Interleukin-6 and the acute phase response
Biochemical Journal - Tập 265 Số 3 - Trang 621-636 - 1990
Tổng số: 13,557   
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 10